Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
PR Newswire
WOODCLIFF LAKE, N.J.

WOODCLIFF LAKE, N.J., Nov. 19, 2012 /PRNewswire/ -- In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a donation of $100,000 to the Hurricane Sandy New Jersey Relief Fund as well as a $50,000 donation to the American Red Cross in an effort to help provide relief to the many areas damaged by Hurricane Sandy.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

"The devastation caused by Hurricane Sandy has affected so many people throughout the East Coast, including many of our employees and their relatives, friends and neighbors," said Lonnel Coats, President and CEO of Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd. "We hope these donations will support efforts to help ease the burden and suffering for those whose lives have been disrupted in very challenging ways."

Eisai USA Foundation Inc.

The Eisai USA Foundation Inc. was established in 2008 as part of Eisai's commitment to be a responsible corporate citizen and contribute to the good of the society in which it does business. The Foundation focuses its charitable giving in four areas: health-related initiatives for patients and caregivers, disaster relief efforts, innovation in medical and pharmaceutical sciences, and community activities in the areas where Eisai's U.S. employees live and work.

Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

SOURCE Eisai Inc.

Photo:http://photos.prnewswire.com/prnh/20120413/MM87168LOGO
http://photoarchive.ap.org/

SOURCE: Eisai Inc.

Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross

PR Newswire

WOODCLIFF LAKE, N.J., Nov. 19, 2012 /PRNewswire/ -- In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a donation of $100,000 to the Hurricane Sandy New Jersey Relief Fund as well as a $50,000 donation to the American Red Cross in an effort to help provide relief to the many areas damaged by Hurricane Sandy.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

"The devastation caused by Hurricane Sandy has affected so many people throughout the East Coast, including many of our employees and their relatives, friends and neighbors," said Lonnel Coats, President and CEO of Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd. "We hope these donations will support efforts to help ease the burden and suffering for those whose lives have been disrupted in very challenging ways."  

Eisai USA Foundation Inc.

The Eisai USA Foundation Inc. was established in 2008 as part of Eisai's commitment to be a responsible corporate citizen and contribute to the good of the society in which it does business. The Foundation focuses its charitable giving in four areas: health-related initiatives for patients and caregivers, disaster relief efforts, innovation in medical and pharmaceutical sciences, and community activities in the areas where Eisai's U.S. employees live and work.  

Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.

SOURCE Eisai Inc.

CONTACT: Media Inquiries - Lynn Kenney, Eisai Inc., +1-201-746-2294; Investor Inquiries - Alex Scott, Eisai Inc., +1-201-746-2177

Web Site: http://www.eisai.com

Type Press Release

Date Released November 19, 2012

RECENT RELEASES
Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
SUBSCRIBE TO OUR NEWS
* Required Fields